These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Prognostic value of PAX3/7-FOXO1 fusion status in alveolar rhabdomyosarcoma: Systematic review and meta-analysis. Kubo T; Shimose S; Fujimori J; Furuta T; Ochi M Crit Rev Oncol Hematol; 2015 Oct; 96(1):46-53. PubMed ID: 26008753 [TBL] [Abstract][Full Text] [Related]
3. PAX3/7-FOXO1 fusion status in older rhabdomyosarcoma patient population by fluorescent in situ hybridization. Dumont SN; Lazar AJ; Bridge JA; Benjamin RS; Trent JC J Cancer Res Clin Oncol; 2012 Feb; 138(2):213-20. PubMed ID: 22089931 [TBL] [Abstract][Full Text] [Related]
4. PAX-FOXO1 fusion status in children and adolescents with alveolar rhabdomyosarcoma: Impact on clinical, pathological, and survival features. Raze T; Lapouble E; Lacour B; Guissou S; Defachelles AS; Gaspar N; Delattre O; Pierron G; Desandes E Pediatr Blood Cancer; 2023 Apr; 70(4):e30228. PubMed ID: 36722003 [TBL] [Abstract][Full Text] [Related]
5. Alveolar rhabdomyosarcoma-associated proteins PAX3/FOXO1A and PAX7/FOXO1A suppress the transcriptional activity of MyoD-target genes in muscle stem cells. Calhabeu F; Hayashi S; Morgan JE; Relaix F; Zammit PS Oncogene; 2013 Jan; 32(5):651-62. PubMed ID: 22710712 [TBL] [Abstract][Full Text] [Related]
6. Targeting KDM4 for treating PAX3-FOXO1-driven alveolar rhabdomyosarcoma. Singh S; Abu-Zaid A; Jin H; Fang J; Wu Q; Wang T; Feng H; Quarni W; Shao Y; Maxham L; Abdolvahabi A; Yun MK; Vaithiyalingam S; Tan H; Bowling J; Honnell V; Young B; Guo Y; Bajpai R; Pruett-Miller SM; Grosveld GC; Hatley M; Xu B; Fan Y; Wu G; Chen EY; Chen T; Lewis PW; Rankovic Z; Li Y; Murphy AJ; Easton J; Peng J; Chen X; Wang R; White SW; Davidoff AM; Yang J Sci Transl Med; 2022 Jul; 14(653):eabq2096. PubMed ID: 35857643 [TBL] [Abstract][Full Text] [Related]
7. Genomic and clinical analysis of fusion gene amplification in rhabdomyosarcoma: a report from the Children's Oncology Group. Duan F; Smith LM; Gustafson DM; Zhang C; Dunlevy MJ; Gastier-Foster JM; Barr FG Genes Chromosomes Cancer; 2012 Jul; 51(7):662-74. PubMed ID: 22447499 [TBL] [Abstract][Full Text] [Related]
8. Alveolar rhabdomyosarcoma of the head and neck region in older adults: genetic characterization and a review of the literature. Yasuda T; Perry KD; Nelson M; Bui MM; Nasir A; Goldschmidt R; Gnepp DR; Bridge JA Hum Pathol; 2009 Mar; 40(3):341-8. PubMed ID: 18973919 [TBL] [Abstract][Full Text] [Related]
10. Divergent transcriptional and transforming properties of PAX3-FOXO1 and PAX7-FOXO1 paralogs. Manceau L; Richard Albert J; Lollini PL; Greenberg MVC; Gilardi-Hebenstreit P; Ribes V PLoS Genet; 2022 May; 18(5):e1009782. PubMed ID: 35604932 [TBL] [Abstract][Full Text] [Related]
11. Regulatory landscape fusion in rhabdomyosarcoma through interactions between the PAX3 promoter and FOXO1 regulatory elements. Vicente-García C; Villarejo-Balcells B; Irastorza-Azcárate I; Naranjo S; Acemel RD; Tena JJ; Rigby PWJ; Devos DP; Gómez-Skarmeta JL; Carvajal JJ Genome Biol; 2017 Jun; 18(1):106. PubMed ID: 28615069 [TBL] [Abstract][Full Text] [Related]
12. Reduced B7-H3 expression by PAX3-FOXO1 knockdown inhibits cellular motility and promotes myogenic differentiation in alveolar rhabdomyosarcoma. Kanayama T; Miyachi M; Sugimoto Y; Yagyu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H Sci Rep; 2021 Sep; 11(1):18802. PubMed ID: 34552155 [TBL] [Abstract][Full Text] [Related]
13. Pax3-fkhr and pax7-fkhr fusion genes impact outcome of alveolar rhabdomyosarcoma in children. Kazanowska B; Reich A; Stegmaier S; Békássy AN; Leuschner I; Chybicka A; Koscielniak E Fetal Pediatr Pathol; 2007; 26(1):17-31. PubMed ID: 17613043 [TBL] [Abstract][Full Text] [Related]
14. PAX3-FOXO1: Zooming in on an "undruggable" target. Wachtel M; Schäfer BW Semin Cancer Biol; 2018 Jun; 50():115-123. PubMed ID: 29146205 [TBL] [Abstract][Full Text] [Related]
15. Acquisition of an oncogenic fusion protein serves as an initial driving mutation by inducing aneuploidy and overriding proliferative defects. Loupe JM; Miller PJ; Bonner BP; Maggi EC; Vijayaraghavan J; Zabaleta J; Taylor CM; Tsien F; Crabtree JS; Hollenbach AD Oncotarget; 2016 Sep; 7(39):62814-62835. PubMed ID: 27588498 [TBL] [Abstract][Full Text] [Related]
16. Piperacetazine Directly Binds to the PAX3::FOXO1 Fusion Protein and Inhibits Its Transcriptional Activity. Nakazawa K; Shaw T; Song YK; Kouassi-Brou M; Molotkova A; Tiwari PB; Chou HC; Wen X; Wei JS; Deniz E; Toretsky JA; Keller C; Barr FG; Khan J; Üren A Cancer Res Commun; 2023 Oct; 3(10):2030-2043. PubMed ID: 37732905 [TBL] [Abstract][Full Text] [Related]
17. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. Sorensen PH; Lynch JC; Qualman SJ; Tirabosco R; Lim JF; Maurer HM; Bridge JA; Crist WM; Triche TJ; Barr FG J Clin Oncol; 2002 Jun; 20(11):2672-9. PubMed ID: 12039929 [TBL] [Abstract][Full Text] [Related]
18. Dense pattern of embryonal rhabdomyosarcoma, a lesion easily confused with alveolar rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Rudzinski ER; Teot LA; Anderson JR; Moore J; Bridge JA; Barr FG; Gastier-Foster JM; Skapek SX; Hawkins DS; Parham DM Am J Clin Pathol; 2013 Jul; 140(1):82-90. PubMed ID: 23765537 [TBL] [Abstract][Full Text] [Related]